| Literature DB >> 10644339 |
H Gahéry-Ségard1, G Pialoux, B Charmeteau, S Sermet, H Poncelet, M Raux, A Tartar, J P Lévy, H Gras-Masse, J G Guillet.
Abstract
We have attempted to develop an anti-human immunodeficiency virus (HIV) lipopeptide vaccine with several HIV-specific long peptides modified by C-terminal addition of a single palmitoyl chain. A mixture of six lipopeptides derived from regulatory or structural HIV-1 proteins (Nef, Gag, and Env) was prepared. A phase I study was conducted to evaluate immunogenicity and tolerance in lipopeptide vaccination of HIV-1-seronegative volunteers given three injections of either 100, 250, or 500 microg of each lipopeptide, with or without immunoadjuvant (QS21). This report analyzes in detail B- and T-cell responses induced by vaccination. The lipopeptide vaccine elicited strong and multiepitopic B- and T-cell responses. Vaccinated subjects produced specific immunoglobulin G antibodies that recognized the Nef and Gag proteins. After the third injection, helper CD4(+)-T-cell responses as well as specific cytotoxic CD8(+) T cells were also obtained. These CD8(+) T cells were able to recognize naturally processed viral proteins. Finally, specific gamma interferon-secreting CD8(+) T cells were also detected ex vivo.Entities:
Mesh:
Substances:
Year: 2000 PMID: 10644339 PMCID: PMC111644 DOI: 10.1128/jvi.74.4.1694-1703.2000
Source DB: PubMed Journal: J Virol ISSN: 0022-538X Impact factor: 5.103